Bitetti Teresa Marie 4

What Happened
Teresa Marie Bitetti, President of the Oncology Business Unit (OBU) at Takeda Pharmaceutical (TAK), was granted 64,988 restricted stock units (RSUs) on April 27, 2026. The Form 4 reports the award with a reported acquisition price of $0 because the RSUs are performance-based and contingent on achievement of specified metrics (core revenue, core operating profit, and R&D milestones). The Compensation Committee determined the final number of RSUs on April 27, 2026 based on those metrics; no cash changed hands at grant.

Key Details

• Transaction date: 2026-04-27; Transaction type: Award/Grant (code A).
• Amount: 64,988 RSUs; reported price/value at grant: $0.
• The filing notes she also has 150,790 RSUs referenced in the report. Vesting schedule for those RSUs: July 1, 2026 (105,044), July 1, 2027 (30,564) and July 1, 2028 (15,182).
• Footnote: Original award was granted July 1, 2023 and became payable based on performance metrics; the Committee determined the payout amount on 2026-04-27.
• Timeliness: Report filed 2026-04-28 for a 2026-04-27 transaction — appears timely.

Context
RSUs are a form of compensation giving the holder a contingent right to receive American Depositary Shares (ADS) if performance conditions and vesting schedules are met. Because this is a compensation award (not an open-market purchase or sale), it should be viewed as part of standard executive pay and not a direct buy/sell signal about near-term insider sentiment.